Ocular Therapeutix Announces 2024 Annual Meeting of Stockholders
Ticker: OCUL · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Virtual Meeting, Stockholder Vote, Ocular Therapeutix
Related Tickers: OCUL
TL;DR
<b>Ocular Therapeutix will hold its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, with the board recommending a 'FOR' vote on five proposals.</b>
AI Summary
OCULAR THERAPEUTIX, INC (OCUL) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Ocular Therapeutix, Inc. will be held on June 12, 2024, at 8:30 a.m. Eastern time. The meeting will be conducted in a virtual-only format, accessible via www.virtualshareholdermeeting.com/OCUL2024. Stockholders can submit questions during the meeting through the virtual meeting website. A list of registered stockholders will be available to record holders during the meeting. The board of directors recommends voting 'FOR' Proposals 1, 2, 3, 4, and 5.
Why It Matters
For investors and stakeholders tracking OCULAR THERAPEUTIX, INC, this filing contains several important signals. The virtual format aims to increase stockholder attendance and participation. This filing serves as the definitive proxy statement, detailing proposals and board recommendations for the upcoming shareholder vote.
Risk Assessment
Risk Level: low — OCULAR THERAPEUTIX, INC shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes indicated.
Analyst Insight
Stockholders should review the proxy materials and vote on the proposed items before the June 12, 2024 meeting.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Pravin U. Dugel, M.D. | Executive Chairman, President and Chief Executive Officer |
Key Numbers
- June 12, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 8:30 a.m. — Meeting Time (Eastern time)
- 5 — Proposals Recommended (Proposals 1, 2, 3, 4 and 5)
Key Players & Entities
- OCULAR THERAPEUTIX, INC (company) — Registrant name
- Pravin U. Dugel, M.D. (person) — Executive Chairman, President and Chief Executive Officer
- June 12, 2024 (date) — Date of Annual Meeting
- 0001558370-24-006110 (other) — Accession Number
- 0001393434 (other) — Central Index Key
- DEF 14A (other) — Form Type
FAQ
When did OCULAR THERAPEUTIX, INC file this DEF 14A?
OCULAR THERAPEUTIX, INC filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by OCULAR THERAPEUTIX, INC (OCUL).
Where can I read the original DEF 14A filing from OCULAR THERAPEUTIX, INC?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by OCULAR THERAPEUTIX, INC.
What are the key takeaways from OCULAR THERAPEUTIX, INC's DEF 14A?
OCULAR THERAPEUTIX, INC filed this DEF 14A on April 29, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Ocular Therapeutix, Inc. will be held on June 12, 2024, at 8:30 a.m. Eastern time.. The meeting will be conducted in a virtual-only format, accessible via www.virtualshareholdermeeting.com/OCUL2024.. Stockholders can submit questions during the meeting through the virtual meeting website..
Is OCULAR THERAPEUTIX, INC a risky investment based on this filing?
Based on this DEF 14A, OCULAR THERAPEUTIX, INC presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational changes indicated.
What should investors do after reading OCULAR THERAPEUTIX, INC's DEF 14A?
Stockholders should review the proxy materials and vote on the proposed items before the June 12, 2024 meeting. The overall sentiment from this filing is neutral.
How does OCULAR THERAPEUTIX, INC compare to its industry peers?
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular conditions.
Are there regulatory concerns for OCULAR THERAPEUTIX, INC?
The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.
Industry Context
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular conditions.
Regulatory Implications
The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.
What Investors Should Do
- Review the proxy statement for details on the five proposals.
- Access the virtual meeting website using the provided control number.
- Cast your vote for or against the proposals before or during the meeting.
Key Dates
- 2024-06-12: Annual Meeting of Stockholders — Virtual-only meeting to vote on company proposals.
Year-Over-Year Comparison
This is the initial filing for the 2024 Annual Meeting of Stockholders.
Filing Stats: 4,819 words · 19 min read · ~16 pages · Grade level 11.5 · Accepted 2024-04-29 16:10:17
Key Financial Figures
- $0.0001 — 4 shares of our common stock, par value $0.0001 per share, or the common stock. Each sh
Filing Documents
- tmb-20240612xdef14a.htm (DEF 14A) — 1221KB
- tmb-20240612xdef14a_a003.jpg (GRAPHIC) — 6KB
- tmb-20240612xdef14a_a004.jpg (GRAPHIC) — 3KB
- tmb-20240612xdef14a_a005.jpg (GRAPHIC) — 3KB
- tmb-20240612xdef14a_a010.jpg (GRAPHIC) — 45KB
- tmb-20240612xdef14a_a011.jpg (GRAPHIC) — 46KB
- tmb-20240612xdef14a_bg001.jpg (GRAPHIC) — 130KB
- tmb-20240612xdef14a_bg002.jpg (GRAPHIC) — 105KB
- 0001558370-24-006110.txt ( ) — 1688KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 15 Summary Compensation Table 15 Narrative Disclosure to Summary Compensation Table 15 Outstanding Equity Awards as of December 31, 2023 19 Employment Agreements with Executive Officers 20 Equity Incentive Plans 22 Securities Authorized for Issuance under Equity Compensation Plans 33 DIRECTOR COMPENSATION 34 Summary Compensation Table 34 Director Compensation Arrangements 35 AUDIT-RELATED MATTERS 36 Audit Committee Report 36 Audit Fees and Services 37 Pre-Approval Policies and Procedures 37 MATTERS TO BE VOTED ON 37 Proposal 1 : Election of Two Class I Directors 37 Proposal 2: Advisory Vote on Named Executive Officer Compensation 38 Proposal 3: Amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as Amended, to Increase the Number of Shares of Common Stock Issuable Thereunder by 7,000,000 Shares 39 Proposal 4: Amendment to our Restated Certificate of Incorporation, as Amended, to Increase the Number of Authorized Shares of Common Stock from 200,000,000 Shares to 400,000,000 Shares 52 Proposal 5: Ratification of the Appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024 53 TRANSACTIONS WITH RELATED PERSONS 54 56 OTHER MATTERS 58 Solicitation of Proxies 58 Householding of Annual Meeting Materials 58 Deadline for Submission of Stockholder Proposals for 2025 Annual Meeting of Stockholders 58 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting : 59 Appendix A A-1 Appendix B B-1 Appendix C C-1 Table of Contents OCULAR THERAPEUTIX, INC. 15 Crosby Drive Bedford, MA 01730 PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON WEDNESDAY, JUNE 12, 2024 Information About the Annual Meeting and Voting This proxy statement is furnished in connection with the solicitat